Long-term response to crisnatol mesylate in patients with glioma

Investigational New Drugs

Volumn 15, Issue 4, 1997, Pages 343-352

  New, P ^a   Vokes, E ^a   Rogers, L ^a   Bazan, C ^a   Hohneker, J ^a   Eble, M ^a   Vilk, P ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Crisnatol mesylate; Efficacy; Malignant glioma; Safety

Indexed keywords

ANTINEOPLASTIC AGENT; CRISNATOL MESYLATE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; GLIOMA; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LONG TERM CARE; MALE; MULTICENTER STUDY; NEUROTOXICITY; OLIGODENDROGLIOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; STOMATITIS; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BRAIN NEOPLASMS; CHRYSENES; COMBINED MODALITY THERAPY; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROPYLENE GLYCOLS; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0031424068     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005968700694     Document Type: Article

References (15)